Glaxo Consumer Has Time To Spread Wings Before Potential Solo Flight
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will not consider spinning off of its consumer health business for two to three years, when it can evaluate its "full value," says CEO Andrew Witty. Sales of the OTC intranasal corticosteroid Flonase Allergy Relief led the firm's US consumer business sales in the latest quarter and throughout 2015.
You may also be interested in...
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.
MoCRA Implementation In US Election Year: Q&A With Attorney Wade Ackerman
Wade Ackerman, partner at Covington & Burling who served previously as senior FDA counsel to US Senate Health Education, Labor & Pensions (HELP) Committee leadership, discusses expectations for FDA activity under modernized cosmetics regulations in 2024.
Ulta’s Footprint Will Grow From US To Mexico In 2025 Under Axo Partnership
Bolingbrook, Ill.-based Ulta Beauty, Inc. will make its international debut in Mexico, a "sizable, growing” market that represents "significant beauty opportunity," says CEO David Kimbell in the firm’s a fiscal 2023 fourth-quarter earnings presentation.